

Irena Misiewicz-Krzeminska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4409946/publications.pdf>

Version: 2024-02-01

38
papers

852
citations

471061

17
h-index

476904

29
g-index

40
all docs

40
docs citations

40
times ranked

1711
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. <i>American Journal of Hematology</i> , 2022, , .	2.0	13
2	Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing. <i>Biomedicines</i> , 2022, 10, 1674.	1.4	3
3	The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2683.	1.0	4
4	Effect of Graphene Family Materials on Multiple Myeloma and Non-Hodgkinâ€™s Lymphoma Cell Lines. <i>Materials</i> , 2020, 13, 3420.	1.3	3
5	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. <i>Blood Advances</i> , 2020, 4, 6023-6033.	2.5	15
6	Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. <i>Blood Cancer Journal</i> , 2019, 9, 90.	2.8	16
7	Factors Regulating microRNA Expression and Function in Multiple Myeloma. <i>Non-coding RNA</i> , 2019, 5, 9.	1.3	29
8	Capillary Nano-immunoassay for Quantification of Proteins from CD138-purified Myeloma Cells. <i>Bio-protocol</i> , 2019, 9, e3267.	0.2	3
9	Determination of AR-V7 in plasma in patients with metastatic prostate cancer using capillary Nano-immunoassay.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16574-e16574.	0.8	0
10	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. <i>Haematologica</i> , 2018, 103, 880-889.	1.7	12
11	A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. <i>Clinical and Translational Oncology</i> , 2017, 19, 1350-1357.	1.2	6
12	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <i>Haematologica</i> , 2017, 102, 2113-2124.	1.7	19
13	Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e4-e5.	0.2	0
14	PD71-08 ANDROGEN RECEPTOR SPLICE VARIANT 7 (AR-V7) IN PATIENTS WITH LOCAL ADVANCED, METASTATIC AND CRPCM: A NOVEL CAPILLARY NANO-INMUNOASSAY TECHNIQUE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
15	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 6602-6615.	3.2	25
16	DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 92.	6.9	23
17	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. <i>Journal of Hematology and Oncology</i> , 2017, 10, 127.	6.9	25
18	Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2003.	1.8	59

#	ARTICLE	IF	CITATIONS
19	Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. <i>PLoS ONE</i> , 2016, 11, e0146722.	1.1	70
20	Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 207-217.	3.2	21
21	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. <i>BMC Cancer</i> , 2015, 15, 238.	1.1	16
22	Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2015, 1849, 353-366.	0.9	22
23	Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism. <i>Blood</i> , 2015, 126, 5353-5353.	0.6	1
24	Prognostic Implications of PIM-2 Expression in Samples from Patients with Chronic Lymphocytic Leukemia and Impact in the Sensitivity to the Pan-PIM Kinase Inhibitor PIM447. <i>Blood</i> , 2015, 126, 2923-2923.	0.6	0
25	Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2001-2001.	0.6	2
26	Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. <i>Haematologica</i> , 2013, 98, 640-648.	1.7	75
27	Isothiocyanate drug interactions in the human adenocarcinoma cell line Caco-2. <i>Molecular and Cellular Biochemistry</i> , 2012, 367, 19-29.	1.4	4
28	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. <i>Haematologica</i> , 2011, 96, 468-471.	1.7	29
29	Does molecular docking reveal alternative chemopreventive mechanism of activation of oxidoreductase by sulforaphane isothiocyanates?. <i>Journal of Molecular Modeling</i> , 2010, 16, 1205-1212.	0.8	9
30	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. <i>Leukemia</i> , 2010, 24, 629-637.	3.3	188
31	Selenitriglycerides affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor. <i>Pharmacological Reports</i> , 2010, 62, 352-361.	1.5	19
32	Influence of protoporphyrin IX amino acid substituents on affinity to human breast adenocarcinoma MCF-7 cells. <i>Biotechnic and Histochemistry</i> , 2009, 84, 17-23.	0.7	3
33	Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[<i>a</i>]pyrene. <i>Journal of Biochemical and Molecular Toxicology</i> , 2009, 23, 18-28.	1.4	41
34	Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205. <i>Cancer Cell International</i> , 2009, 9, 10.	1.8	17
35	The effect of isothiocyanates on CYP1A1 and CYP1A2 activities induced by polycyclic aromatic hydrocarbons in MCF7 cells. <i>Toxicology in Vitro</i> , 2009, 23, 763-771.	1.1	31
36	Mitochondrial localization of P2Y1, P2Y2 and P2Y12 receptors in rat astrocytes and glioma C6 cells. <i>Brain Research Bulletin</i> , 2007, 71, 587-592.	1.4	18

#	ARTICLE	IF	CITATIONS
37	A comparison of the concentrationâ€“effect relationships of PAHs on CYP1A induction in HepG2 and MCF7 cells. Archives of Toxicology, 2007, 81, 183-200.	1.9	31
38	Inhibition of cell cycle and induction of apoptosis by 2-oxohexyl isothiocyanate and alysin in cell lines carrying various inherited BRCA1 mutations. Drug Development Research, 2005, 65, 84-92.	1.4	0